08 February 2021 | News
CT-P59 is approved for the treatment of patients aged 60 years and over, or with at least one underlying medical condition, with mild symptoms of COVID-19, and adult patients with moderate symptoms of COVID- 19
Photo Credit: Freepik
Celltrion Group has announced that the Ministry of Food and Drug Safety (MFDS) of South Korea has granted conditional marketing authorization (MA) for the emergency use of regdanvimab (CT-P59), an anti-COVID-19 monoclonal antibody treatment candidate. Conditional Marketing Authorization allows emergency use of CT-P59 in adult patients aged 60 years and over, or with at least one underlying medical condition (cardiovascular, chronic respiratory disease, diabetes, elevated blood pressure) mild symptoms of COVID-19, and in adult patients with moderate symptoms of COVID-19.
The conditional MA is based on Part 1 of the Phase II / III trial and showed the following results:
“ With the pandemic still raging in Korea, we believe this conditional marketing authorization for regdanvimab represents an important step in the fight against COVID-19,” says Dr HoUng Kim, Ph.D., head of the medical and marketing division of Celltrion Healthcare.
A global Phase III clinical trial is being recruited (1,172 patients planned) for mild to moderate symptoms of COVID-19 at more than 10 sites worldwide to assess the efficacy and safety results of CT -P59. Celltrion is in the process of demonstrating clinical efficacy against COVID-19 for the British and South African variants. The results are expected in the coming days.